Cardiac Rhabdomyosarcoma
Cardiac rhabdomyosarcoma is an aggressive, malignant mesenchymal tumor of the heart striated muscle progenitors. Unlike benign tumors arising from the heart, cardiac rhabdomyosarcoma is distinguished by its invasive growth, local structural invasion, and early metastatic spread. Protheragen focuses on rare cardiovascular diseases, which allows them to offer comprehensive drug research and development services to the unique research problems posed by diseases such as cardiac rhabdomyosarcoma.
Introduction to Cardiac Rhabdomyosarcoma
Cardiac rhabdomyosarcomas account for twenty-one percent of the heart's primary neoplasms, and they are the second most prevalent in adults. This malignant tumor primarily affects middle-aged people, with a median survival time of a few months, which is quite low. Some of the symptoms include arrhythmias, heart failure, and chest pain, which are all nonspecific, depending on the size and location of the tumor within the heart chambers or valves.
Fig.1 Echocardiography delineated a sizable, distinct mass in the left atrium. (Uchida, T., et al., 2020)Pathogenesis of Cardiac Rhabdomyosarcoma
The pathogenesis of cardiac rhabdomyosarcoma is complex, involving the suspected malignant change of primitive mesenchymal cells or undifferentiated multipotent stem cells located in the heart. These cells transform aberrantly along a skeletal muscle pathway and exhibit uncontrolled proliferation through disrupted myogenic differentiation and oncogenic signaling.
Therapeutics Development for Cardiac Rhabdomyosarcoma
| Drug Name | Mechanism of Action | Targets | Research Phase |
|---|---|---|---|
| Eribulin | It attaches to tubulin and prevents the growth stage of microtubules, subsequently resulting in mitotic arrest and eventual cell apoptosis. | Tubulin | Approved |
| Pazopanib | Inhibitor of receptor tyrosine kinase (RTK). | VEGFR | Approved |
| Doxorubicin | Leads to free radical generation, integrating with DNA, resulting in DNA fragmentation and apoptosis. | DNA | Approved |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
From diagnostics and therapeutics development to preclinical research and disease model creation, Protheragen integrates all services into a one-stop solution to satisfy biotechnology firms or researchers' needs. Precision capabilities combined with clever strategy from early-stage verification equip all steps required for an innovative therapy creation. Not only are the processes accelerated in terms of drug discovery, but also the resulting specialized research programs are tailored towards a demand for rare cardiovascular diseases.
Therapeutic Development Services
Diverse Platforms
Animal Model Development for Cardiac Rhabdomyosarcoma
Creation of effective animal models for cardiac rhabdomyosarcoma will aid in drug discovery. Our custom animal models are designed according to each client's needs, thereby maximizing relevancy and efficiency for the particular objectives. This guarantees that meaningful and anticipatory models are ready, corresponding to critical stages throughout the pharmaceutical development processes.
Genetically Engineered Animal Models
These changes pertain to modifying the animal genome through targeted mutations or overexpression of specific oncogenes associated with human rhabdomyosarcoma.
- SM22α-SV40 T Antigen Transgenic Model
- Other models
Pharmacokinetics and Drug Safety Research Services
In addition to our animal model development services, Protheragen performs important investigational work such as detailed pharmacokinetics, pharmacodynamics, and safety evaluation studies. These evaluations are critical for obtaining a comprehensive understanding of drug action in vivo and, most importantly, protecting individuals. With this complete portfolio of services consolidated within one center, we enable our partners to innovate therapies for rare cardiovascular disorders like cardiac rhabdomyosarcoma. Should these services be of interest to you, please get in touch with us.
Reference
- Uchida, Tetsuro et al. "Primary Biatrial Cardiac Rhabdomyosarcoma." Brazilian journal of cardiovascular surgery 35.3 (2020): 399-401.
For research use only, not for clinical use.